One shot of radiation may ease cancer symptoms as well as multiple sessions
NCT ID NCT04516135
First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 1 time
Summary
This study compares a single session of palliative radiation therapy to the standard multiple sessions for people with gynecologic cancers that have spread. The goal is to see if one treatment can improve symptoms like pain and bleeding and boost quality of life just as well. About 28 participants will be enrolled, and researchers will also study how radiation affects the immune system.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
28 people
The number who actually took part.
- Started
-
Jan 2021
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically or cytologically documented gynecologic cancer with prior or current evidence of metastatic disease * Measurable pelvic disease with any pain and/or bleeding * Eastern Cooperative Oncology Group (ECOG) performance status of =\< 3 * Estimated life expectancy \> 3 months at discretion of treating physician * Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication * Patient able to provide properly obtained written informed consent * Gynecologic Section Radiation Oncology Quality Assurance (QA) for eligibility for single fraction radiation treatment Exclusion Criteria: * Prior pelvic radiation therapy that would make treatment unsafe at the discretion of the treating physician * Systemic therapy concurrently or within 21 days of first dose of radiation * Concurrent participation in another interventional radiation therapy trial concurrently or within 30 days of study consent. Note: Patients who are participating in systemic clinical trials and non-interventional clinical trials (e.g., QOL, imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of participation * Known second malignancy that requires active treatment (at the discretion of the primary investigator) * Documented psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * Pregnant or breastfeeding at any point starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic malignant female reproductive system neoplasm are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cooper Hospital University
Camden, New Jersey, 08103, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
OhioHealth
Columbus, Ohio, 43215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.